If you need more lookups,
subscriptions start at $34 USD/month.
Thomas Morel Location
Basel, BS, CH
Thomas Morel Work
Patient-Centred Outcomes Research and Policy Lead, Global Clinical Development @ (January 2017 - Present)
Associate Director, Early Products Market Access and PRO Strategy @ (September 2013 - January 2017)
Industry Chair, Critical Path Parkinson's Patient-Centric Endpoints Group @ (November 2023 - December 2025)
Member of the Therapies Scientific Committee (TSC) @ (June 2019 - May 2025)
Member - Innovative methodologies for clinical studies in rare diseases taskforce @ European Joint Programme on Rare Diseases (January 2019 - December 2022)
Research Fellow, Clinical Pharmacology and Pharmacotherapy @ (October 2011 - December 2022)
Taskforce member - Orphan Drug Development Guidebook @ (January 2018 - March 2019)
Team Lead - Taskforce on Patient-Centered Outcome Measures in Rare Diseases @ (January 2016 - December 2017)
Manager, Health Economics and Outcomes Research group @ (September 2007 - September 2013)
EU public affairs consultant @ Houston Consulting Europe (May 2003 - July 2007)
Thomas Morel Education
KU Leuven 2014-2019
King's College London 2004-2005
The London School of Economics and Political Science (LSE) 2001-2002
Thomas Morel Summary
Thomas Morel, based in Basel, BS, CH, is currently a Patient-Centred Outcomes Research and Policy Lead, Global Clinical Development at UCB. Thomas Morel brings experience from previous roles at UCB, Critical Path Institute (C-Path), International Rare Diseases Research Consortium (IRDiRC) and European Joint Programme on Rare Diseases. Thomas Morel holds a 2014 - 2019 KU Leuven. Thomas Morel has 3 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Thomas Morel?
Find contact details for 700 million professionals.